PTC Therapeutics Inc. appointed Matthew Klein, M.D., as chief development officer and Eric Pauwels as chief business officer.
The board of directors of BioSpecifics Technologies Corp. appointed Joseph Truitt as interim CEO. He will also serve on the company’s board of directors. Truitt succeeds J. Kevin Buchi, who […]
Tatsuya Kaihara was tapped as corporate officer and head of North America business of Santen Pharmaceutical Co. Ltd.
Q BioMed Inc., a commercial-stage biotech company, appointed Geoff Fatzinger as the global head of regulatory affairs.
EVERSANA a leading independent provider of global commercial services to the life sciences industry, appointed Ed Cox to executive VP, strategic alliances and global head of the company’s new digital medicine practice area.
Bolt Biotherapeutics Inc., a private clinical-stage biotechnology company, tapped Edith Perez, M.D., as chief medical officer.
ORIC Pharmaceuticals Inc., a privately held clinical-stage oncology company, appointed Christian V. Kuhlen, M.D., general counsel.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, named Marc de Somer, M.D., as senior VP, clinical development and safety, and Judy Caron, Ph.D., as VP of drug development.
Seneca Biopharma Inc., a clinical-stage biopharmaceutical company, appointed Matthew W. Kalnik, Ph.D. as president and chief operating officer and Dane R. Saglio as chief financial officer. Seneca also promoted Thomas Hazel, Ph.D., to the newly created position of senior VP of research and development.
